Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
41 studies found for:    Open Studies | "Gastrointestinal Stromal Tumors"

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Gastrointestinal Stromal Tumors" (41 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Conditions: Gastrointestinal Stromal Tumors;   KIT +;   Resected Gastrointestinal Stromal Tumors;   Non-metastatic;   High Risk of Recurrence
Intervention: Drug: Imatinib maintenance
2 Recruiting A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: Famitinib
3 Recruiting A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Masitinib;   Drug: Sunitinib
4 Unknown † A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: masitinib (AB1010);   Drug: imatinib
5 Recruiting Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Advanced Gastrointestinal Stromal Tumors
Intervention: Drug: PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.
6 Recruiting A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation;   Drug: sunitinib malate
7 Not yet recruiting A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: BBI503
8 Unknown † Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Imatinib mesylate
9 Not yet recruiting Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: dovitinib plus imatinib
10 Recruiting Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Conditions: Gastrointestinal Stromal Tumor;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: Dasatinib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
11 Unknown † A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore
Condition: Gastrointestinal Stromal Tumors
Intervention:
12 Not yet recruiting Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Pazopanib;   Drug: Trametinib
13 Recruiting MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: MEK162;   Drug: Imatinib Mesylate (Gleevec®; STI571; NSC #716051);   Other: Blood draws;   Procedure: biopsy
14 Recruiting Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
15 Recruiting A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
Condition: Gastrointestinal Stromal Tumour
Interventions: Drug: Regorafenib;   Drug: imatinib
16 Recruiting BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Condition: Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: BGJ398;   Drug: Imatinib Mesylate
17 Unknown † Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Pazopanib
18 Recruiting A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
19 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
20 Recruiting Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy
Conditions: Gastrointestinal Stromal Tumor;   Major Gastrectomy
Intervention: Dietary Supplement: cola
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years